Latest Conference Articles

Explore the urgent need for diabetes specialists and the American College of Diabetology's efforts to enhance care through education and certification.

​​At SLEEP 2025, Levine highlighted how the Syn-One skin test detects early signs of Parkinson Disease in patients with iRBD with the observation of phosphorylated alpha-synuclein.

Hosts sit down for a deep dive into The Diabetes Collective and what it's like operating a diabetes clinic in the modern healthcare landscape.

In this Q&A, Narcisse shared what the association between greater oral microbiome diversity and longer sleep in teens and young adults could mean for early-life disease prevention.

Leading experts discuss managing atopic dermatitis in skin of color in a live recording from the 2025 Revolutionizing Atopic Dermatitis Conference.

Verma went over the STRIDE trial evaluating the GLP-1 RA and its latest findings presented at ADA Scientific Sessions.

Li and Shao discussed the heavy disease burden of type 2 diabetes in the VA population and outlined the VA MOVE! study.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 notable dermatology updates from the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference.

At SLEEP 2025, Sachdeva discussed the evolving legal implications of AI use in sleep medicine, including clinician liability, informed consent, and responsible integration into care.

Mifepristone shows promise in improving glycemic control and reducing weight in patients with hypercortisolism and type 2 diabetes.

Maridebart cafraglutide shows potential as a monthly treatment for obesity and type 2 diabetes, demonstrating significant weight loss and glycemic improvements.

At SLEEP 2025, HCPLive spoke with Narcisse about NHANES-based findings suggesting longer sleep duration is associated with richer and more diverse oral microbiomes.

Sandforth emphasized the important of achieving prediabetes remission for preventing T2D as seen in his new research.

Explore groundbreaking findings from the REDEFINE trials on CagriSema's impact on weight loss and diabetes management at ADA 2025.

Philis-Tsimikas shared the latest findings demonstrating inferiority after switching from daily basal insulin to weekly insulin efsitora.

Kevin Sayer joins the program to discuss the latest from Dexcom and preview where the business is headed in an evolving diabetes landscape.

A new study reveals once-weekly efsitora alfa effectively lowers blood glucose in type 2 diabetes.

Steger discussed findings from a 6-month lifestyle investigating TRE+ER and IER.

CagriSema shows weight loss results in recent trials comparable to existing interventions.

Xue discussed her research developing a personalized prediction algorithm for predicting responders to a DPP-style intervention.

A phase 3 trial reveals ecnoglutide significantly reduces body weight in overweight patients, showcasing its potential as a novel obesity treatment.

A new study reveals hybrid closed-loop technology significantly improves glucose control for pregnant women with T1D.

Automated insulin delivery systems enhance blood glucose control for pregnant women with type 1 diabetes, potentially advancing diabetes care.

Semaglutide 7.2 mg shows promising results, achieving a mean 21% weight loss in obesity treatment.

The ACHIEVE-1 trial reveals orforglipron's potential as a breakthrough treatment for type 2 diabetes.

New research reveals amycretin's promising potential for weight loss in obesity treatment, advancing to phase 3 trials for effective management options.

Most participants (83%) did not require exogenous insulin 1 year after zimislecel (VX-880) infusion.

New ADA guidelines enhance obesity care, focusing on personalized treatment, bias reduction, and inclusive practices to improve patient outcomes.